Stockreport

Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis

Vascular Biogenics Ltd. - Ordinary Shares  (VBLT) 
Last vascular biogenics ltd. - ordinary shares earnings: 11/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: vblrx.com
PDF TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that a study entitled “MOSPD2: A Novel Therapeutic Target for the [Read more]